Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors

European Journal of Cancer

Volumn 45, Issue 18, 2009, Pages 3213-3219

  Skinner, Roderick ^a,b   Parry, Annie ^a   Price, Lisa ^a   Cole, Michael ^b   Craft, Alan W ^b   Pearson, Andrew D J ^b,c  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Carboplatin; Child; Cisplatin; Drug toxicity; Kidney; Kidney glomerulus; Kidney tubules; Late sequelae

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; METHOTREXATE; TENIPOSIDE;

ARTICLE; CALCIUM CELL LEVEL; CHILDHOOD CANCER; COHORT ANALYSIS; CONTINUOUS INFUSION; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CALCIUM; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; KIDNEY DISEASES; KIDNEY TUBULES; MAGNESIUM; MALE; NEOPLASMS; SEVERITY OF ILLNESS INDEX; SURVIVORS; TREATMENT OUTCOME;

EID: 70450161199     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.06.032     Document Type: Article

References (29)

1. Kroll M.E., Passmore S.J., Stiller C.A., et al. Childhood cancer - UK. In: Toms J.R. (Ed). Cancer stats monograph 2004 (2004), Cancer Research UK, London 63-72
2. Campbell J., Wallace W.H.B., Bhatti L.A., Stockton D.L., Rapson T., and Brewster D.H. Childhood cancer in Scotland: trends in incidence, mortality and survival 1975-1999 (2004), NHS Scotland Information and Statistics Division, Edinburgh
3. Craft A.W., and Pearson A.J. Three decades of chemotherapy for childhood cancer: from cure 'at any cost' to cure 'at least cost'. Cancer Surv 8 (1989) 605-629
4. Womer R.B., Pritchard J., and Barratt T.M. Renal toxicity of cisplatin in children. J Pediatr 106 (1985) 659-663
5. Mann J.R., Raafat F., Robinson K., et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18 (2000) 3809-3818
6. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., and Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 9 (2008) 247-256
7. English M.W., Skinner R., Pearson A.D.J., Price L., Wyllie R., and Craft A.W. Dose-related nephrotoxicity of carboplatin in children. Brit J Cancer 81 (1999) 336-341
8. Skinner R., Pearson A.D.J., English M.W., et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77 (1998) 1677-1682
9. Skinner R., Pearson A.D.J., Coulthard M.G., et al. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28 (1991) 81-92
10. Chantler C., and Barratt T.M. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 47 (1972) 613-617
11. Hjorth L., Wiebe T., and Karpman D. Correct evaluation of renal glomerular filtration rate requires clearance assays. Pediatr Nephrol 17 (2002) 847-851
12. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
13. Brock P.R., Koliouskas D.E., Barratt T.M., Yeomans E., and Pritchard J. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118 (1991) 531-534
14. Ariceta G., Rodriguez-Soriano J., Vallo A., and Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28 (1997) 35-40
15. Madias N.E., and Harrington J.T. Platinum nephrotoxicity. Am J Med 65 (1978) 307-314
16. Lam M., and Adelstein D.J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8 (1986) 164-169
17. Stohr W., Paulides M., Bielack S., et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48 (2007) 140-147
18. Bashir H., Crom D., Metzger M., Mulcahey J., Jones D., and Hudson M.M. Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. Pediatr Blood Cancer 49 (2007) 867-869
19. Panichpisal K., Angulo-Pernett F., Selhi S., and Nugent K.M. Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol 7 (2006) 10
20. Goren M.P. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Med Pediatr Oncol 41 (2003) 186-189
21. Harrell R.M., Sibley R., and Vogelzang N.J. Renal vascular lesions after chemotherapy with vinblastine, bleomycin and cisplatin. Am J Med 23 (1982) 429-433
22. Canpolat C., Pearson P., and Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 74 (1994) 3059-3062
23. Brandt L.J., and Broadbent V. Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?. Med Pediatr Oncol 21 (1993) 31-35
24. Pinkerton C.R., Broadbent V., Horwich A., et al. JEB - a carboplatin based regimen for malignant germ cell tumours in children. Br J Cancer 62 (1990) 257-262
25. Bergeron C., Dubourg L., Chastagner P., et al. Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study. Pediatr Blood Cancer 45 (2005) 32-36
26. Butani L., West D.C., and Taylor D.S. End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation. Pediatr Transplant 7 (2003) 408-412
27. Pabla N., and Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73 (2008) 994-1007
28. Daugaard G., Abildgaard U., Holsten-Rathlou N.H., Bruunshuus I., Bucher D., and Leyssac P.P. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44 (1988) 164-172
29. Daugaard G., Rossing N., and Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21 (1988) 163-167